Novel observations with FDOPA-PET imaging after early nigrostriatal damage

Movement Disorders

Volumn 16, Issue 5, 2001, Pages 838-848

  Yee, R E ^a   Irwin, I ^b   Milonas, C ^c   Stout, D B ^a   Huang, S C ^a   Shoghi Jadid, K ^a   Satyamurthy, N ^a   Delanney, L E ^b   Togasaki, D M ^b   Farahani, K F ^a   Delfani, K ^c   Janson, A M ^c   Phelps, M E ^a   Langston, J W ^b   Barrio, J R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PARKINSON S INSTITUTE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

6 F18 fluoro L DOPA; Optical fractionator; Parkinson's disease; Positron emission tomography; Squirrel monkeys; Stereology

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 FLUORODOPA F 18; CARBIDOPA; DOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN INJURY; CAUDATE NUCLEUS; CELL COUNT; CELL LOSS; CLINICAL OBSERVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DECARBOXYLATION; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG UPTAKE; FEMALE; MALE; MEASUREMENT; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; REVIEW; SQUIRREL MONKEY; STEREOLOGY; SUBSTANTIA NIGRA; SYMPTOMATOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; FLUORINE RADIOISOTOPES; MALE; NEURAL PATHWAYS; NEUROTOXINS; PARKINSONIAN DISORDERS; SAIMIRI; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035470373     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1168     Document Type: Review

References (60)

1. Koller WC. When does Parkinson's disease begin? Neurology 1992;42:S27-31.
2. Berheimer H, Birkmayer W, Hornykiewcz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455.
3. Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of the clinical diagnosis of Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatr 1992;55:181-184.
4. Gjedde A, Léger GC, Cumming P, et al. Striatal L-DOPA decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis. J Neurochem 1993;61:1538-1541.
5. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
6. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
7. 18F]Fluoro-L-DOPA probes dopamine turnover rates in central dopaminergic structures. J Neurosci Res 1990;27:487-493.
8. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993;34:331-338.
9. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999;45:577-582.
10. Wszolek ZK, Pfeiffer RF, Bhatt MH, Schelper RL, Cordes M, Snow BJ, Rodnitzky RL, Wolters EC, Arwert F, Calne DB. Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. Ann Neurol 1992;32:312-320.
11. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984;292:390-394.
12. Irwin I, DeLanney LE, Forno LS, Finnegan KT, DiMonte DA, Langston JW. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res 1990; 531:242-252.
13. Yee RE, Huang S-C, Stout DB, et al. Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in vivo and in vitro investigations. J Neurochem 2000;74:1147-1157.
14. Hoffman JM, Melega WP, Hawk TC, et al. The effects of carbidopa administration on 6-[F-18]fluoro-L-dopa kinetics in positron emission tomography. J Nucl Med 1992;33:1472-1477.
15. 18F]Fluoro-L-DOPA metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography. Brain Res 1991;543:271-276.
16. Stout DB, Huang S-C, Melega WP, Raleigh MJ, Phelps ME, Barrio JR. Effects of large neutral amino acid concentrations on 6-[F-18]fluoro-L-DOPA kinetics. J Cereb Blood Flow Metab 1998;18: 43-51.
17. Meltzer CC, Bryan RN, Holcomb HH, et al. Anatomical localization for PET using MR imaging. J Comput Assist Tomogr 1990; 14:418-426.
18. Lin KP, Huang S-C, Yu D-C, Melega WP, Barrio JR, Phelps ME. Automated image registration for FDOPA PET studies. Phys Med Biol 1996;41:2775-2788.
19. 18F]fluoro-DOPA in human positron emission tomographic studies. J Cereb Blood Flow Metab 1991;11:898-913.
20. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time data. J Cereb Blood Flow Metab 1983;3:1-7.
21. Langston JW, Quik M, Petzinger G, Jakowec M, DiMonte DA. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol 2000;47:S79-89.
22. Janson AM, Moller A. Chronic nicotine treatment counteracts nigral cell loss induced by partial meso-diencephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 1993; 57:931-941.
23. Chan P, DiMonte DA, Langston JW, Janson AM. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J Pharmacol Exp Ther 1997;280:439-446.
24. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
25. Parent A. Mammal substantia nigra: a duel structure. In: Wiley J. ed. Comparative neurobiology of the basal ganglia. New York: New York Press; 1986;202-214.
26. Emmers R, Akert K. A stereotaxic atlas of the brain of the squirrel monkey (saimiri squireus). Wisconsin: University of Wisconsin Press; 1963.
27. Sterio DC. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 1984;134;127-136.
28. West MJ, Slomianka L, Gundersen HJG. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991; 231:482-497.
29. Walters TL, Irwin I, Delfani K, Langston JW, Janson AM. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Exp Neurol 1999;156:62-70.
30. Gundersen HJG. Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson. J Microsc 1986; 143:3-45.
31. Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stererology and its prediction. J Microsc 1987;147:229-263.
32. Gundersen HJ, Jensen EB, Kiêu K, Nielsen J. The efficiency of systematic sampling in stereology-reconsidered. J Microsc 1999; 193:199-211.
33. Keeping ES. Exact tests on samples from normal population. In: Introduction to statistical inference. New York: Dover; 1995;193-197.
34. Kaakkola S, Teräväinen H. Animal models of parkinsonism. Pharmacol Toxicol 1990:67;95-100.
35. Price DL, Sisodia SS, Koo EH, et al. Neuronal disorders: studies of animal models and human diseases. Toxicol Pathol 1990;18:128-137.
36. Stout DB. Small monkeys as clinical models for the study of the central dopaminergic system using positron emission tomography. Ph. D thesis. Los Angeles: University of California, 1999.
37. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin LJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
38. German DC, Dubach M, Askari S, Speciale SG, Bowden DM. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience 1988;24:161-174.
39. Mytilineou C, Cohen G, Heikkila RE. 1-Methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture. Neurosci Lett 1985;57:19-24.
40. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47:493-503.
41. Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ . Relationship among nigrostriatal denervation, parkinsonism, and dyskinesia in the MPTP primate model. Mov Disord 2000;15:459-466.
42. Pakkenberg B, Moller A, Gundersen HJG, Dam AM, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiat 1991; 54:30-33.
43. Ma SY, Röyttä M, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci 1997;151:83-87.
44. Zhu MY, Juorio AV, Paterson IA, Boulton AA. Regulation of aromatic L-amino acid decarboxylase by dopamine receptors in the rat brain. J Neurochem 1992;58:636-641.
45. Rossetti ZL, Silvia CP, Krajnc D, Neff NH, Hadjiconstantinou M. Aromatic L-amino acid decarboxylase is modulated by D1 dopamine receptors in rat retina. J Neurochem 1990;54:787-791.
46. Bezard E, Boraud T, Bioulac B, Gross CE. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience 1997;2:399-404.
47. Gasper P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann Neurol 1991;30:365-374.
48. Berger TW, Kaul S, Stricker EM, Zigmond MJ. Hyperinervation of the striatum by the dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Res 1985;336:354-358.
49. Fiandaca MS, Kordower JH, Hanssen JT, Jiao SS, Gash DM. Adrenal medullary autografts into the basal ganglia of cebus monkeys: injury-induced regeneration. Exp Neurol 1988;102:76-91.
50. Björklund A, Lindvall O. Dopamine in dendrites of the substantia nigra neurons: suggestions for a role in dendritic terminals. Brain Res 1975;83:531-537.
51. Gale K, Guidotti A, Costa E. Dopamine-sensitive adenylate cyclase: location in the substantia nigra. Science 1977;195:503-505.
52. Cheramy A, Leviel V, Glowinski J. Dendritic release of dopamine in the substantia nigra. Nature 1981;289:537-542.
53. H-GABA release from slices of rat substantia nigra in vitro. Nature 1977;268:652-654.
54. Agid Y, Javoy F, Glowinski L. Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigrostriatal dopaminergic system in rat. Nature 1973;245:150-151.
55. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 1993;60:140-147.
56. Rose S, Nomoto SM, Kelly E, Kilpatrick G, Jenner P, Marsden CD. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci Lett 1989;101:305-310.
57. Grenhoff J, Janson AM, Svensson TH, Fuxe K. Chronic continuous nicotine treatment causes decreased burst firing of nigral dopamine neurons in rats partially hemitransected at the mesodiencephalic junction. Brain Res 1991;562:347-351.
58. Barrio JR, Huang S-C, Yu D-C, et al. Radiofluorinated L-m-tyrosines: new in vivo probes for the central dopamine biochemistry. J Cereb Blood Flow Metab 1996;16:667-678.
59. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 1989;4:371-377.
60. 11C]tetrabenazine and positron emission tomography. J Neurochem 1993;60:2315-2318.